Agathobaculum butyriciproducens Shows Neuroprotective Effects in a 6-OHDAInduced Mouse Model of Parkinson’s Disease

키워드

참고문헌 (77)

1. Kalia LV, "Parkinson's disease", Lancet, 386, pp.896~912 (2015)
2. Hughes AJ, "Accuracy of clinical diagnosis of idiopathic Parkinson's disease : a clinicopathological study of 100 cases", J. Neurol. Neurosurg. Psychiatry, 55, pp.181~184 (1992)
3. Rana AQ, "Parkinson's disease : a review of non-motor symptoms", Expert Rev. Neurother, 15, pp.549~562 (2015)
4. Schapira AHV, "Non-motor features of Parkinson disease", Nat. Rev. Neurosci, 18, pp.435~450 (2017)
5. Fasano A, "Gastrointestinal dysfunction in Parkinson's disease", Lancet Neurol, 14, pp.625~639 (2015)
6. Susanne Fonseca Santos, "The Gut and Parkinson's Disease—A Bidirectional Pathway", Frontiers in Neurology, 10 (2019), Frontiers Media SA[DOI]
7. Cersosimo MG, "Gastrointestinal manifestations in Parkinson's disease : prevalence and occurrence before motor symptoms", J. Neurol, 260, pp.1332~1338 (2013)
8. Martinez-Martin P, "The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease", Mov. Disord, 26, pp.399~406 (2011)
9. Cryan JF, "The microbiota-gut-brain Axis", Physiol. Rev, 99, pp.1877~2013 (2019)
10. Braak H, "Idiopathic Parkinson's disease : possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen", J. Neural. Transm(Vienna), 110, pp.517~536 (2003)
11. Neufeld KM, "Reduced anxiety-like behavior and central neurochemical change in germ-free mice", Neurogastroenterol. Motil, 23, pp.255~264 (2011)[DOI]
12. Kawase T, "Gut microbiota of mice putatively modifies amino acid metabolism in the host brain", Br. J. Nutr, 117, pp.775~783 (2017)
13. Bruce-Keller AJ, "Obese-type gut microbiota induce neurobehavioral changes in the absence of obesity", Biol. Psychiatry, 77, pp.607~615 (2015)
14. Zheng P, "Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism", Mol. Psychiatry, 21, pp.786~796 (2016)
15. Ansari F, "The effects of probiotics and prebiotics on mental disorders : A review on depression, anxiety, alzheimer, and autism spectrum disorders", Curr. Pharm. Biotechnol, 21, pp.555~565 (2020)
16. Hongli Huang, "Fecal microbiota transplantation to treat Parkinson's disease with constipation", Medicine, 98(26), pp.e16163~ (2019), Ovid Technologies (Wolters Kluwer Health)[DOI]
17. Hsieh TH, "Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson's disease", Brain Sci, 10, pp.206~ (2020)
18. Srivastav S, "Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity", J. Nutr. Biochem, 69, pp.73~86 (2019)
19. Castelli V, "Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson's disease models", Aging(Albany NY), 12, pp.4641~4659 (2020)
20. Keshavarzian A, "Colonic bacterial composition in Parkinson's disease", Mov. Disord, 30, pp.1351~1360 (2015)
21. Rani L, "Unravelling the role of gut microbiota in Parkinson's disease progression : Pathogenic and therapeutic implications", Neurosci. Res, 168, pp.100~112 (2021)
22. Ahn S, "Agathobaculum butyriciproducens gen. nov.  sp. nov., a strict anaerobic, butyrate-producing gut bacterium isolated from human faeces and reclassification of Eubacterium desmolans as Agathobaculum desmolans comb. nov", Int. J. Syst. Evol. Microbiol, 66, pp.3656~3661 (2016)
23. Go J, "Human gut microbiota Agathobaculum butyriciproducens improves cognitive impairment in LPS-induced and APP", PS1 mouse models of Alzheimer's disease, 2021, pp.86, 96~108
24. Yan J, "Inflammatory response in Parkinson's disease(Review)", Mol. Med. Rep, 10, pp.2223~2233 (2014)
25. Troncoso-Escudero P, "Outside in : Unraveling the role of neuroinflammation in the progression of Parkinson's disease", Front. Neurol, 9, pp.860~ (2018)
26. Hirsch EC, "Neuroinflammation in Parkinson's disease : a target for neuroprotection?", Lancet Neurol, 8, pp.382~397 (2009)
27. Gagne JJ, "Anti-inflammatory drugs and risk of Parkinson disease : a meta-analysis", Neurology, 74, pp.995~1002 (2010)
28. Whitton PS, "Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease", Curr. Opin. Investig. Drugs, 11, pp.788~794 (2010)
29. Everard A, "Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity", Proc. Natl. Acad. Sci. USA, 110, pp.9066~9071 (2013)
30. Park HY, "Gadd45beta ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model", Neurobiol. Dis, 89, pp.169~179 (2016)
31. Park HY, "Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease", J. Neurosci, 34, pp.11744~11753 (2014)
32. Ryu YK, "Metformin inhibits the development of L-DOPA-induced dyskinesia in a murine model of Parkinson's disease", Mol. Neurobiol, 55, pp.5715~5726 (2018)
33. Keith BJ, "The mouse brain in stereotaxic coordinates, Third edition Ed" (2007), Elsevier
34. Ryu YK, "Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging", Neuropharmacology, 175, pp.108173~ (2020)
35. Go J, "Piperlongumine decreases cognitive impairment and improves hippocampal function in aged mice", Int. J. Mol. Med, 42, pp.1875~1884 (2018)
36. Park TS, "Humulus japonicus inhibits the progression of Alzheimer's disease in a APP", PS1 transgenic mouse model, 2017, pp.39, 21~30
37. Albin RL, "The functional anatomy of basal ganglia disorders", Trends Neurosci, 12, pp.366~375 (1989)
38. 류영경, "Humulus japonicus Prevents Dopaminergic Neuron Death in 6-Hydroxydopamine-Induced Models of Parkinson’s Disease", Journal of Medicinal Food, 20(2), pp.116~123 (2017), 한국식품영양과학회[DOI]
39. Haavik J, "Tyrosine hydroxylase and Parkinson's disease", Mol. Neurobiol, 16, pp.285~309 (1998)
40. Franke TF, "PI3K : downstream AKTion blocks apoptosis", Cell, 88, pp.435~437 (1997)
41. Glinka Y, "Mechanism of 6-hydroxydopamine neurotoxicity", J. Neural. Transm. Suppl, 50, pp.55~66 (1997)
42. Thiruvengadam M, "Bioactive compounds in oxidative stress-mediated diseases : Targeting the NRF2", ARE signaling pathway and epigenetic regulation, 2021, pp.10, 1859~
43. Kramer BC, "Alterations in the cellular distribution of bcl-2, bcl-x and bax in the adult rat substantia nigra following striatal 6-hydroxydopamine lesions", J. Neurocytol, 33, pp.213~223 (2004)
44. Fulling C, "Gut microbe to brain signaling : What happens in vagus", Neuron, 101, pp.998~1002 (2019)
45. Hayashi A, "A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice", Cell Host Microbe, 13, pp.711~722 (2013)
46. Xu R, "The role of the probiotic Akkermansia muciniphila in brain functions : insights underpinning therapeutic potential", Crit. Rev. Microbiol, 11, pp.1~26 (2022)
47. Deumens R, "Modeling Parkinson's disease in rats : an evaluation of 6-OHDA lesions of the nigrostriatal pathway", Exp. Neurol, 175, pp.303~317 (2002)
48. Zhu Y, "Overview of tyrosine hydroxylase in Parkinson's disease", CNS Neurol. Disord. Drug Targets, 11, pp.350~358 (2012)
49. Yang L, "The role of insulin", IGF-1, Akt, pp.GSK3beta signaling in Parkinson's disease dementia, Front. Neurosci[DOI]
50. Chen G, "Glycogen synthase kinase 3beta(GSK3beta)mediates 6-hydroxydopamineinduced neuronal death", FASEB J, 18, pp.1162~1164 (2004)
51. Chung CY, "An endogenous serine", threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease, 2007, pp.27, 8314~8323
52. Doble BW, "GSK-3 : tricks of the trade for a multi-tasking kinase", J. Cell Sci, 116, pp.1175~1186 (2003)
53. Jope RS, "The glamour and gloom of glycogen synthase kinase-3", Trends Biochem. Sci, 29, pp.95~102 (2004)
54. Beaulieu JM, "Beyond cAMP : The regulation of Akt and GSK3 by dopamine receptors", Front. Mol. Neurosci, 4, pp.38~ (2011)
55. Quesada A, "PI3 kinase", Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease, 2008, pp.68, 632~644
56. Aleyasin H, "DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway", Proc. Natl. Acad. Sci. USA, 107, pp.3186~3191 (2010)
57. Xie CL, "Inhibition of Glycogen Synthase Kinase-3beta(GSK-3beta)as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats", Sci. Rep, 6, pp.23527~ (2016)
58. Krishnankutty A, "In vivo regulation of glycogen synthase kinase 3beta activity in neurons and brains", Sci. Rep, 7, pp.8602~ (2017)
59. Aaseth J, "Prevention of progression in Parkinson's disease", Biometals, 31, pp.737~747 (2018)
60. Percario S, "Oxidative stress in Parkinson's disease : Potential benefits of antioxidant supplementation", Oxid. Med. Cell Longev, 2020, pp.2360872~ (2020)
61. de Oliveira MR, "Protective effect of carnosic acid against paraquat-induced redox impairment and mitochondrial dysfunction in SH-SY5Y cells : Role for PI3K", Akt, Toxicol. In Vitro, pp.2016, 32[DOI]
62. Li L, "Nrf2", ARE pathway activation, HO-1 and NQO1 induction by polychlorinated biphenyl quinone is associated with reactive oxygen species and PI3K, Chem. Biol. Interact, pp.2014, 209[DOI]
63. Reiter RJ, "Oxidative damage in the central nervous system : protection by melatonin", Prog. Neurobiol, 56, pp.359~384 (1998)
64. Miao L, "Regulation of superoxide dismutase genes : implications in disease", Free Radic. Biol. Med, 47, pp.344~356 (2009)
65. Oh YJ, "Overexpression of Bcl-2 attenuates MPP+, but not 6-ODHA, induced cell death in a dopaminergic neuronal cell line", Neurobiol. Dis, 2, pp.157~167 (1995)
66. Sun J, "Fecal microbiota transplantation alleviated Alzheimer's disease-like pathogenesis in APP", PS1 transgenic mice, 2019, pp.9, 189~
67. Zhao Z, "Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiotagut-brain axis", Microbiome, 9, pp.226~ (2021)
68. Liddelow SA, "Reactive astrocytes : Production, function, and therapeutic potential", Immunity, 46, pp.957~967 (2017)
69. Stevens B, "The classical complement cascade mediates CNS synapse elimination", Cell, 131, pp.1164~1178 (2007)
70. Liddelow SA, "Neurotoxic reactive astrocytes are induced by activated microglia", Nature, 541, pp.481~487 (2017)
71. Gorshkov K, "Astrocytes as targets for drug discovery", Drug Discov. Today, 23, pp.673~680 (2018)
72. Nicholson JK, "Host-gut microbiota metabolic interactions", Science, 336, pp.1262~1267 (2012)
73. Holscher HD, "Dietary fiber and prebiotics and the gastrointestinal microbiota", Gut Microbes, 8, pp.172~184 (2017)
74. Cantu-Jungles TM, "Potential of prebiotic butyrogenic fibers in Parkinson's disease", Front. Neurol, 10, pp.663~ (2019)
75. Claesson MJ, "Composition, variability, and temporal stability of the intestinal microbiota of the elderly", Proc. Natl. Acad. Sci. USA, 108(1), pp.4586~4591 (2011)
76. Unger MM, "Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls", Parkinsonism Relat. Disord, 32, pp.66~72 (2016)
77. Liu J, "Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1", J. Neurol. Sci, 381, pp.176~181 (2017)

관련 논문AI추천